These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26060823)

  • 1. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
    Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
    J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
    Chamarthi B; Ezrokhi M; Rutty D; Cincotta AH
    Postgrad Med; 2016 Nov; 128(8):761-769. PubMed ID: 27687032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
    Gaziano JM; Cincotta AH; Vinik A; Blonde L; Bohannon N; Scranton R
    J Am Heart Assoc; 2012 Oct; 1(5):e002279. PubMed ID: 23316290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.
    Gaziano JM; Cincotta AH; O'Connor CM; Ezrokhi M; Rutty D; Ma ZJ; Scranton RE
    Diabetes Care; 2010 Jul; 33(7):1503-8. PubMed ID: 20332352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
    Roe ED; Chamarthi B; Raskin P
    J Diabetes Res; 2015; 2015():834903. PubMed ID: 26060825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
    Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
    Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Bromocriptine-QR as an Adjunctive Therapy on Glycemic Control in Subjects with Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
    Yanto TA; Budiputri CL; Muljono MP; Chandra S
    J ASEAN Fed Endocr Soc; 2024; 39(1):95-105. PubMed ID: 38863918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
    Schwartz SS; Zangeneh F
    Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quick-release bromocriptine for treatment of type 2 diabetes.
    Mikhail N
    Curr Drug Deliv; 2011 Sep; 8(5):511-6. PubMed ID: 21696353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.
    Raskin P; Cincotta AH
    Expert Rev Endocrinol Metab; 2016 Mar; 11(2):113-148. PubMed ID: 30058874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.
    Cincotta AH; Cersosimo E; Alatrach M; Ezrokhi M; Agyin C; Adams J; Chilton R; Triplitt C; Chamarthi B; Cominos N; DeFronzo RA
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
    Scranton R; Cincotta A
    Expert Opin Pharmacother; 2010 Feb; 11(2):269-79. PubMed ID: 20030567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
    Lamos EM; Levitt DL; Munir KM
    Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
    Siamashvili M; Davis S
    Expert Opin Pharmacother; 2021 Feb; 22(2):241-247. PubMed ID: 33030357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.
    Bell DS
    Postgrad Med; 2012 Sep; 124(5):121-35. PubMed ID: 23095432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects.
    Cincotta AH
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.
    Scranton RE; Gaziano JM; Rutty D; Ezrokhi M; Cincotta A
    BMC Endocr Disord; 2007 Jun; 7():3. PubMed ID: 17592632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian-timed quick-release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus.
    Chamarthi B; Vinik A; Ezrokhi M; Cincotta AH
    Endocrinol Diabetes Metab; 2020 Jan; 3(1):e00101. PubMed ID: 31922028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.